CUE
Income statement / Annual
Last year (2023), Cue Biopharma, Inc.'s total revenue was $5.49 M,
an increase of 340.88% from the previous year.
In 2023, Cue Biopharma, Inc.'s net income was -$50.73 M.
See Cue Biopharma, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$5.49 M
|
$1.25 M
|
$14.94 M
|
$3.15 M
|
$3.46 M
|
$1.14 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$38.10 M |
$1.81 M |
-$1.78 M |
$33.55 M |
$27.49 M |
$28.54 M |
$419,568.00 |
$202,085.00 |
$44,815.00 |
| Gross Profit |
-$32.61 M |
-$560,828.00 |
$16.72 M |
-$30.39 M |
-$24.03 M |
-$27.40 M |
-$419,568.00 |
-$202,085.00 |
-$44,815.00 |
| Gross Profit Ratio |
-5.94 |
-0.45 |
1.12 |
-9.63 |
-6.95 |
-23.98 |
0 |
0 |
0 |
| Research and Development
Expenses |
$40.80 M
|
$38.58 M
|
$41.35 M
|
$33.55 M
|
$27.49 M
|
$28.54 M
|
$18.90 M
|
$5.69 M
|
$1.50 M
|
| General & Administrative
Expenses |
$16.68 M
|
$16.17 M
|
$17.31 M
|
$14.65 M
|
$12.74 M
|
$11.30 M
|
$4.33 M
|
$1.97 M
|
$425,081.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$16.68 M
|
$16.17 M
|
$17.31 M
|
$14.65 M
|
$12.74 M
|
$11.30 M
|
$4.33 M
|
$1.97 M
|
$425,081.00
|
| Other Expenses |
-$37.94 M |
$0.00 |
$0.00 |
$0.00 |
$64,000.00 |
$165,337.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$19.54 M |
$54.75 M |
$58.65 M |
$48.20 M |
$40.23 M |
$39.84 M |
$23.23 M |
$7.66 M |
$1.93 M |
| Cost And Expenses |
$57.64 M |
$54.75 M |
$58.65 M |
$48.20 M |
$40.23 M |
$39.84 M |
$23.23 M |
$7.66 M |
$1.93 M |
| Interest Income |
$2.66 M |
$928,242.00 |
$45,898.00 |
$463,914.00 |
$419,000.00 |
$376,008.00 |
$35.00 |
$52.00 |
$0.00 |
| Interest Expense |
$1.25 M |
$713,815.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.44 M
|
$1.81 M
|
-$1.78 M
|
$1.06 M
|
$5.35 M
|
$760,011.00
|
$419,568.00
|
$202,085.00
|
$44,815.00
|
| EBITDA |
-$46.05 M
|
-$50.49 M
|
-$45.44 M
|
-$43.99 M
|
-$35.96 M
|
-$37.94 M
|
-$22.81 M
|
-$7.46 M
|
-$1.88 M
|
| EBITDA Ratio |
-8.39 |
-40.77 |
-2.93 |
-13.94 |
-10.63 |
-33.2 |
0 |
0 |
0 |
| Operating Income Ratio
|
-9.5
|
-42.74
|
-2.93
|
-14.28
|
-10.63
|
-33.87
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.42 M
|
$215,000.00
|
$45,898.00
|
$463,914.00
|
$482,790.00
|
$541,345.00
|
$35.00
|
$52.00
|
$0.00
|
| Income Before Tax |
-$50.73 M |
-$53.01 M |
-$43.67 M |
-$44.58 M |
-$36.29 M |
-$38.16 M |
-$23.23 M |
-$7.66 M |
-$1.93 M |
| Income Before Tax Ratio
|
-9.24
|
-42.57
|
-2.92
|
-14.13
|
-10.49
|
-33.39
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$214,427.00 |
$495,000.00 |
$206,250.00 |
$412,000.00 |
$825,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Net Income |
-$50.73 M |
-$52.80 M |
-$44.16 M |
-$44.78 M |
-$36.70 M |
-$38.98 M |
-$23.23 M |
-$7.66 M |
-$1.93 M |
| Net Income Ratio |
-9.24 |
-42.4 |
-2.96 |
-14.2 |
-10.61 |
-34.12 |
0 |
0 |
0 |
| EPS |
-1.11 |
-1.48 |
-1.41 |
-1.56 |
-1.66 |
-1.94 |
-1.13 |
-0.37 |
-0.0934 |
| EPS Diluted |
-1.11 |
-1.48 |
-1.41 |
-1.56 |
-1.66 |
-1.94 |
-1.13 |
-0.37 |
-0.0934 |
| Weighted Average Shares
Out |
$45.75 M
|
$35.65 M
|
$31.29 M
|
$28.69 M
|
$22.04 M
|
$20.13 M
|
$20.64 M
|
$20.64 M
|
$20.64 M
|
| Weighted Average Shares
Out Diluted |
$45.75 M
|
$35.65 M
|
$31.29 M
|
$28.69 M
|
$22.04 M
|
$20.13 M
|
$20.64 M
|
$20.64 M
|
$20.64 M
|
| Link |
|
|
|
|
|
|
|
|
|
